In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Minerva patient lift recall

This article was originally published in The Gray Sheet

Executive Summary

Medibo initiates Class I recall of 64 units of the battery-powered patient lifts Aug. 4 due to mechanical problems. Some hanger bars detached because of missing spring washers, causing patients to fall, the agency says. Further Minerva problems cited include loose foot-pedal assembly bolts and faulty actuator brackets on the mast assembly, resulting in lift instability. The recall continues a rising trend in Class I recalls (1"The Gray Sheet" July 19, 2004, p. 16). The Minerva patient lift is technically identical to Arjo's Minstrel, recalled earlier this year...

You may also be interested in...

Zeiss Visulink Reflects Rise In Device Class I Recall Notifications

Carl Zeiss Meditec's Class I voluntary recall is part of a recent uptick in FDA announcements related to the most serious type of device recalls

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts